Renovaro Biosciences Alpha and Beta Analysis
| RENBDelisted Stock | 1.27 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Renovaro Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Renovaro Biosciences over a specified time horizon. Remember, high Renovaro Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Renovaro Biosciences' market risk premium analysis include:
Beta 0.0831 | Alpha (1.09) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Renovaro |
Renovaro Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Renovaro Biosciences market risk premium is the additional return an investor will receive from holding Renovaro Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Renovaro Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Renovaro Biosciences' performance over market.| α | -1.09 | β | 0.08 |
Renovaro Biosciences Fundamentals Vs Peers
Comparing Renovaro Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Renovaro Biosciences' direct or indirect competition across all of the common fundamentals between Renovaro Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Renovaro Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Renovaro Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Renovaro Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Renovaro Biosciences to competition |
| Fundamentals | Renovaro Biosciences | Peer Average |
| Return On Equity | -0.53 | -0.31 |
| Return On Asset | -0.0841 | -0.14 |
| Current Valuation | 298.83 M | 16.62 B |
| Shares Outstanding | 231.78 M | 571.82 M |
| Shares Owned By Insiders | 36.71 % | 10.09 % |
| Shares Owned By Institutions | 12.16 % | 39.21 % |
| Number Of Shares Shorted | 1.22 M | 4.71 M |
Renovaro Biosciences Opportunities
Renovaro Biosciences Return and Market Media
The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Is This a Bottoming Phase for Renovaro Inc. - Wealth Building Stock Market Ideas Based on Momentum - beatles.ru | 07/29/2025 |
2 | Renovaro Inc. Mentioned in RealClearDefense Article on AI and Biodefense Risks | 08/08/2025 |
3 | PREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA Kahn Swick Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale ... | 08/20/2025 |
4 | Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnosti... | 08/27/2025 |
5 | Renovaro BioSciences to change corporate name to Lunai Bioworks - MSN | 09/03/2025 |
6 | Lunai Bioworks Strengthens European Strategy Through Restructuring | 09/08/2025 |
7 | Discretionary transaction by Brink Karen of tradable shares of Renovaro Biosciences subject to Rule 16b-3 | 09/10/2025 |
8 | Lunai Bioworks subsidiary BioSymetrics and Brigham and Womens Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeuti... | 09/11/2025 |
9 | Lunai Bioworks, Inc. to Effect 101 Reverse Stock Split | 09/24/2025 |
10 | Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinsons Disease, Positioning for Strategic Pharma Partnerships | 09/25/2025 |
About Renovaro Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Renovaro or other delisted stocks. Alpha measures the amount that position in Renovaro Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Renovaro Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Renovaro Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Renovaro Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Renovaro Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Renovaro Biosciences. Please utilize our Beneish M Score to check the likelihood of Renovaro Biosciences' management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Renovaro Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Renovaro Stock
If you are still planning to invest in Renovaro Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Renovaro Biosciences' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |